ZAP-70 expression and prognosis in chronic lymphocytic leukaemia - PubMed (original) (raw)

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

Jenny A Orchard et al. Lancet. 2004.

Abstract

Background: Chronic lymphocytic leukaemia (CLL) is a heterogeneous disease; many patients never need treatment, whereas some have poor outcomes. New treatments, which can induce complete remissions, allow patients with poor outlook to be treated while they are still asymptomatic. Whether or not the IgVH gene is mutated is the best predictor of clinical outcome, but this assay is unsuited to the routine laboratory. The gene coding for ZAP-70, a tyrosine kinase protein normally expressed in T and NK cells, has been shown by gene-expression profiling to be differentially expressed between patients with mutated and unmutated IgVH genes. We assessed whether ZAP-70 could be used as a prognostic marker in CLL.

Methods: We developed a flow cytometry assay for ZAP-70 protein expression and investigated its concordance with ZAP-70 mRNA expression, IgVH gene mutational status, and clinical outcome in 167 patients with CLL.

Findings: We showed high concordance between ZAP-70 protein expression and IgVH gene mutations. 108 patients (65%) had mutated IgVH genes and were ZAP-70 negative; 46 (28%) had unmutated IgVH genes and were ZAP-70 positive. Findings were discordant in 13 patients: six (4%) had mutated IgVH genes but were ZAP-70 positive, and seven (4%) had unmutated IgVH genes and were ZAP-70 negative. Expression of mRNA showed 97% concordance with ZAP-70 protein. Median survival was 24.4 years (95% CI 15.1-33.8) in ZAP-70 negative patients and 9.3 years (7.0-11.5) in those who were ZAP-70 positive (hazard ratio 5.5, 2.8-.8).

Interpretation: ZAP-70 protein, which can be measured by flow cytometry in the general laboratory, is a reliable prognostic marker in CLL, equivalent to that of IgVH gene mutational status.

PubMed Disclaimer

Cited by

CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes.
Gonzalez D, Else M, Wren D, Usai M, Buhl AM, Parker A, Oscier D, Morgan G, Catovsky D. Gonzalez D, et al. Haematologica. 2013 Feb;98(2):274-8. doi: 10.3324/haematol.2012.070201. Epub 2012 Aug 16. Haematologica. 2013. PMID: 22899580 Free PMC article.
Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.
Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S, Else M, Matutes E, Catovsky D; Chronic Lymphocytic Leukaemia Working Group, UK National Cancer Research Institute. Oscier D, et al. Haematologica. 2010 Oct;95(10):1705-12. doi: 10.3324/haematol.2010.025338. Epub 2010 May 29. Haematologica. 2010. PMID: 20511662 Free PMC article.
A perspective on DNA microarrays in pathology research and practice.
Pollack JR. Pollack JR. Am J Pathol. 2007 Aug;171(2):375-85. doi: 10.2353/ajpath.2007.070342. Epub 2007 Jun 28. Am J Pathol. 2007. PMID: 17600117 Free PMC article.
Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA.
Stamatopoulos B, Haibe-Kains B, Equeter C, Meuleman N, Sorée A, De Bruyn C, Hanosset D, Bron D, Martiat P, Lagneaux L. Stamatopoulos B, et al. Haematologica. 2009 Jun;94(6):790-9. doi: 10.3324/haematol.2008.002626. Epub 2009 Apr 18. Haematologica. 2009. PMID: 19377082 Free PMC article.
miR deregulation in CLL.
Balatti V, Pekarky Y, Rizzotto L, Croce CM. Balatti V, et al. Adv Exp Med Biol. 2013;792:309-25. doi: 10.1007/978-1-4614-8051-8_14. Adv Exp Med Biol. 2013. PMID: 24014303 Free PMC article. Review.

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia - PubMed (original) (raw)